Published in N Engl J Med on October 14, 2009
The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One (2012) 1.14
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
Unintended effects of orphan product designation for rare neurological diseases. Ann Neurol (2012) 0.87
Market exclusivity for biologics. N Engl J Med (2010) 0.79
Controlled release of biologics for the treatment of type 2 diabetes. J Control Release (2015) 0.75
Market exclusivity for biologics. N Engl J Med (2010) 0.75
Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. Eur J Drug Metab Pharmacokinet (2015) 0.75
Adalimumab pricing and market exclusivity for biologics. N Engl J Med (2010) 0.75
Cost-effectiveness of proton beam therapy for intraocular melanoma. PLoS One (2015) 0.75
Patents associated with high-cost drugs in Australia. PLoS One (2013) 0.75
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol (2005) 8.77
Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005) 8.44
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57
A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47
Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med (2014) 4.99
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol (2003) 4.95
Self-management education programs in chronic disease: a systematic review and methodological critique of the literature. Arch Intern Med (2004) 4.68
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
New FDA breakthrough-drug category--implications for patients. N Engl J Med (2014) 4.30
Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst (2002) 4.16
A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98
Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA (2010) 3.85
Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol (2007) 3.82
The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med (2010) 3.78
The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med (2006) 3.64
Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med (2014) 3.62
Rethinking global access to vaccines. BMJ (2008) 3.60
The 21st Century Cures Act--Will It Take Us Back in Time? N Engl J Med (2015) 3.52
Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ (2013) 3.43
The quality of pharmacologic care for vulnerable older patients. Ann Intern Med (2004) 3.34
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33
The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med (2011) 3.27
The medical device excise tax--over before it begins? N Engl J Med (2013) 3.25
Rethinking the use of physicians as hired expert lecturers. Ann Intern Med (2014) 3.22
Drug-review deadlines and safety problems. N Engl J Med (2008) 3.16
Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med (2013) 3.13
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.04
Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation (2004) 2.98
University-based science and biotechnology products: defining the boundaries of intellectual property. JAMA (2005) 2.95
Compliance with osteoporosis medications. Arch Intern Med (2005) 2.91
Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med (2002) 2.85
Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med (2002) 2.82
Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol (2006) 2.81
High-cost generic drugs--implications for patients and policymakers. N Engl J Med (2014) 2.79
Internet marketing of herbal products. JAMA (2003) 2.77
Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA (2004) 2.77
Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution--a simulation study. Am J Epidemiol (2010) 2.74
Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA (2010) 2.71
Sending pharma better signals. Science (2005) 2.69
Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis (2005) 2.65
Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res (2003) 2.65
Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA (2011) 2.60
Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol (2008) 2.58
Performance of propensity score calibration--a simulation study. Am J Epidemiol (2007) 2.56
Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol (2005) 2.55
Practical, legal, and ethical issues in expanded access to investigational drugs. N Engl J Med (2015) 2.53
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med (2004) 2.52
Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation (2008) 2.42
Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology (2005) 2.38
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.37
Racial differences in screening for prostate cancer in the elderly. Arch Intern Med (2004) 2.34
Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care (2007) 2.31
Arthritis self-management education programs: a meta-analysis of the effect on pain and disability. Arthritis Rheum (2003) 2.30
Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum (2007) 2.18
Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol (2002) 2.15
Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med (2012) 2.13
Assessing health state utilities in elderly patients at cardiovascular risk. Med Decis Making (2006) 2.12
Research ethics. Paying patients for their tissue: the legacy of Henrietta Lacks. Science (2012) 2.10
Trouble getting started: predictors of primary medication nonadherence. Am J Med (2011) 2.09
Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy. J Clin Epidemiol (2002) 2.09
Origins of medical innovation: the case of coronary artery stents. Circ Cardiovasc Qual Outcomes (2012) 2.08
Every clinician deserves an un-sales rep. MedGenMed (2007) 2.03
Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiol Drug Saf (2013) 2.01
FDA regulation of mobile health technologies. N Engl J Med (2014) 1.96
Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum (2006) 1.95
Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med (2012) 1.94
Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum (2006) 1.94
Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Saf (2009) 1.91
Regulation of medical devices in the United States and European Union. N Engl J Med (2012) 1.89
A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol (2005) 1.83
The variability and quality of medication container labels. Arch Intern Med (2007) 1.83
Medical students' exposure to and attitudes about the pharmaceutical industry: a systematic review. PLoS Med (2011) 1.82
Hydroxyethyl starch and change in renal function in patients undergoing coronary artery bypass graft surgery. Kidney Int (2003) 1.80
Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data. J Gen Intern Med (2004) 1.79
Ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: a quantitative assessment. Heart Rhythm (2010) 1.78
Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med (2014) 1.78
A propensity analysis of late versus early nephrologist referral and mortality on dialysis. J Am Soc Nephrol (2003) 1.78
Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. Hypertension (2005) 1.77
Prescription opioid use among older adults with arthritis or low back pain. Arthritis Rheum (2006) 1.77
Relationship between COX-2 specific inhibitors and hypertension. Hypertension (2004) 1.75
The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf (2011) 1.74
Creating a medical, ethical, and legal framework for complex living kidney donors. Clin J Am Soc Nephrol (2006) 1.74
Guided prescription of psychotropic medications for geriatric inpatients. Arch Intern Med (2005) 1.72
Effect of content and format of prescription drug labels on readability, understanding, and medication use: a systematic review. Ann Pharmacother (2007) 1.70
Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs (2010) 1.67
The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis (2005) 1.67
Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med (2007) 1.62